Austria Ulrich Schlick, deputy managing director of the German Chamber of Commerce in Austria, discusses the Chamber’s role in facilitating business opportunities for German companies in Austria and vice versa. He also provides an overview of the cultural ties and differences between the countries and the potential of Austria for German…
Tunisia Christophe Sauer, president at Sephire, the association of innovative pharmaceutical companies in Tunisia, talks us through the challenges that innovative MNCs are facing in the country, especially in terms of pricing, but also highlights the important efforts that have been made in public-private dialogues. Mr. Sauer, could you please introduce…
ARM Annie Hubert, Senior Director, EU Section & Public Policy for the Alliance for Regenerative Medicine (ARM) describes some of the issues that companies in the advanced therapies field are facing in terms of market access and stakeholder education in Europe, as well as some of the key breakthroughs that European…
Canada Jim Keon, President of the CGPA, discusses how the Canadian generics industry is adapting to the current period of political transition and how it engages in talks with the government and other stakeholders to educate them about the costly and complex process of generic drug production. Jim, we had the…
Tunisia Habib Gaïda, general manager of the Tunisian-French Chamber of Commerce and Industry, shares his determination to encourage the return of French companies in Tunisia to counterbalance the presence of new incumbents in the country such as China and Turkey. The chamber is primarily concerned with the promotion of partnerships and…
Bulgaria Prof. Ilko Getov, PhD, MSc Pharm, MHM, president of the Bulgarian Pharmaceutical Union (BPhU) provides a fascinating insight into the changes sweeping across the pharmaceutical industry in Bulgaria and reveals the country’s determination to modernize its offerings in line with the highest in Europe. Could you please introduce yourself to…
Bulgaria Deyan Denev, Executive Director of the Association of the Research-Based Pharmaceutical Manufacturers in Bulgaria (ARPharM), shares a clear overview of the role of innovative pharmaceutical players within Bulgaria, and the association’s commitment to working with government to enlarge patients’ access to innovative medicines. How has the overall situation for innovative…
Austria Daniela Homan, executive director of AmCham Austria, the representative and advocating voice of US companies in Austria, provides an in-depth analysis of the strategies being employed by the chamber and highlights the current concerns of US subsidiary CEOs in Austria. She also provides an overview of how the market has…
USA Douglas Peddicord, executive director of ACRO, introduces ACRO’s mission, the evolution of the CRO space in the US and globally, and how the latest political developments are affecting the association and its members. Can you begin by introducing ACRO and its mission? “We at ACRO have always focused on advocating…
Colombia Marisol Sanchez, executive president of ANDI’s Medical Devices Chamber in Colombia, speaks about the opportunities and challenges in the country’s medtech sector, the industry’s strong ethical code, the key role of the Chamber in supporting its members to navigate the regulatory landscape, as well as the need for a sustainable…
Austria Robert Sauermann, head of the department of pharmaceutical affairs in the Main Association of Austrian Social Security Institutions, which publishes the national code of reimbursement, provides an in-depth look into how drugs are assessed before being placed onto the reimbursement list as well as the challenges faced when negotiating with…
Austria Dr. Jan Oliver Huber, secretary general of the Association of the Pharmaceutical Industry in Austria, or PHARMIG, which represents 120 member companies and 95 percent of the medicinal product market in Austria, discusses the changing dynamics of the Austrian healthcare sector and its price referencing system. He also gives his…
See our Cookie Privacy Policy Here
